Driving innovation that will deliver improved public services, create new better-paid jobs and grow the economy.
Oral Answers to Questions is a regularly scheduled appearance where the Secretary of State and junior minister will answer at the Dispatch Box questions from backbench MPs
Other Commons Chamber appearances can be:Westminster Hall debates are performed in response to backbench MPs or e-petitions asking for a Minister to address a detailed issue
Written Statements are made when a current event is not sufficiently significant to require an Oral Statement, but the House is required to be informed.
Department for Science, Innovation & Technology does not have Bills currently before Parliament
Department for Science, Innovation & Technology has not passed any Acts during the 2024 Parliament
e-Petitions are administered by Parliament and allow members of the public to express support for a particular issue.
If an e-petition reaches 10,000 signatures the Government will issue a written response.
If an e-petition reaches 100,000 signatures the petition becomes eligible for a Parliamentary debate (usually Monday 4.30pm in Westminster Hall).
The Online Safety Act will require social media platforms to take more responsibility for the safety of their users. Platforms will need to remove all illegal abusive content and protect children from harmful content, including hateful and abusive content.
Where anonymous abuse does not meet the criminal threshold, adult users of the largest services (Category 1) will have the choice to filter out content from non-verified users. Those services must also offer user empowerment tools to adult users, which when applied will reduce the likelihood that they are exposed to certain legal content, including abusive content.
The Online Safety Act will require social media platforms to take more responsibility for the safety of their users. Platforms will need to remove all illegal abusive content and protect children from harmful content, including hateful and abusive content.
Where anonymous abuse does not meet the criminal threshold, adult users of the largest services (Category 1) will have the choice to filter out content from non-verified users. Those services must also offer user empowerment tools to adult users, which when applied will reduce the likelihood that they are exposed to certain legal content, including abusive content.
The government is working with Ofcom to implement the Online Safety Act as quickly and effectively as possible. The Act, once implemented, will require services to tackle illegal content online and protect children from harmful content. On 16 December 2024, Ofcom reached a significant milestone by publishing the first draft illegal harms code which sets out measures that services can take to comply with their new duties.
Ofcom will reach several more milestones over the coming months including publication of its: child access guidance; age assurance guidance for pornography publishers; draft guidance on protecting women and girls online; and the draft child safety code.
Opinions vary as to what constitutes ‘good’ mobile connectivity and I have raised my concerns about the reporting of connectivity with Ofcom, but according to Ofcom’s Connected Nations report (published on 5 December 2024), 4G indoor premises coverage is available from all four mobile operators in 68% of premises in your constituency, with 97% from at least one. This leaves 3% of premises (around 1,500 premises) with no 4G indoor coverage from any operator. Premises includes all buildings not just homes.
Through the Shared Rural Network, we are continuing to deliver 4G mobile connectivity to places where there is either limited or no coverage at all.
Whilst the transition from the analogue landline network to voice over internet protocol is an industry-led process, Ofcom and Government are working together with communications providers to ensure consumers and sectors are protected and prepared for the upgrade process.
Opinions vary as to what constitutes ‘good’ mobile connectivity and I have raised my concerns about the reporting of connectivity with Ofcom, but according to Ofcom’s Connected Nations report (published on 5 December 2024), 4G indoor premises coverage is available from all four mobile operators in 68% of premises in your constituency, with 97% from at least one. This leaves 3% of premises (around 1,500 premises) with no 4G indoor coverage from any operator. Premises includes all buildings not just homes.
Through the Shared Rural Network, we are continuing to deliver 4G mobile connectivity to places where there is either limited or no coverage at all.
Whilst the transition from the analogue landline network to voice over internet protocol is an industry-led process, Ofcom and Government are working together with communications providers to ensure consumers and sectors are protected and prepared for the upgrade process.
The Government is determined to ensure that any and all risks incurred during the industry-led migration from the analogue landline network to voice over internet protocol are mitigated. On 18 November 2024, the Department published guidance for communication providers on how to identify and support customers when their landline migrates. This includes customers who are landline dependent, many of which live in rural communities.
The Department also published a checklist of activities that communication providers should take before migrating customers to voice over internet protocol without their active consent. We expect providers to meet the safeguards set out in this checklist to keep customers – including those in rural communities - safe throughout the migration.
Ofcom reports that 2024 saw 45% more service incidents on the Public Switched Telephone Network (PSTN) compared to 2023, resulting in a 55% increase in the number of service hours lost. Retaining the PSTN would increase the risks of outages which would have a negative impact on consumers.
The digital sector is of vital importance to the UK economy, and overall employment in the sector has increased between 2022-2023. DSIT continues to analyse trends in employment in the sector. The government is committed to growing the pipeline of skilled talent, both to support UK companies and provide opportunities for all to access good jobs in the sector.
The government recognises that access to the internet is increasingly essential for full participation in society and has taken steps to ensure households across the UK are able to access fast, reliable mobile and broadband services.
More than 25 providers now offer low-cost mobile and broadband packages for households in receipt of Universal Credit and some other means tested benefits (up from 10 providers in September 2022), with the average price of a broadband social tariff being £17.41 per month. Social tariffs could provide consumers with savings of over £220 per year on their fixed broadband bills.
Public sector organisations are responsible for their own websites and DSIT has no plans to review or issue guidance on the use of web tags. All public sector organisations must comply with data protection laws.
According to the independent website Thinkbroadband.com, 99% of premises in the Newbury constituency can already access superfast broadband speeds (>=30 Mbps), and almost 87% can access a gigabit-capable broadband connection.
To extend gigabit-capable coverage further, approximately 1,600 premises in the constituency are currently included in a Project Gigabit contract being delivered by Openreach. This includes eligible premises in Kintbury, Boxford, Lambourn and Great Shefford.
Additionally, a significant number of premises in the constituency are expected to be connected through the commercial market.
The digital switchover is an industry led programme. Customers in rural communities will not have their landlines migrated to Voice over Internet Protocol (VoIP) without an available stable internet connection (VoIP only requires a minimum speed of 0.5mbps).
The Government has taken several initiatives to boost rural connectivity and mobile coverage throughout the UK, including Project Gigabit, the Shared Rural Network deal with the industry, and publishing the Wireless Infrastructure Strategy 2023.
AI has the potential to increase productivity and create high value jobs in the UK economy. This government is committed to making sure AI opportunities are available across the UK and today we have launched the AI Opportunities Action Plan to reach this goal.
The government is committed to preparing workers with the skills needed for future jobs by working with industry to responsibly adopt AI across all sectors. Skills England, DSIT and the Industrial Strategy Council will unite businesses, training partners, unions, and government to assess and address the country's AI and digital skills needs.
The Online Safety Act puts new duties on social media companies and search services, making them responsible for their users’ safety. These include new duties tackling illegal content and activity which affects women and girls, including intimate image abuse, exploitation and other forms of abuse.
Ofcom will publish draft guidance in February, detailing measures services can take to tackle violence against women and girls (VAWG) online.
The government has set an unprecedented mission to halve VAWG in a decade by improving the police and criminal justice system response, relentlessly pursuing perpetrators, and providing victim support. The steps Ofcom is taking helps supports this mission by tackling harmful content online.
Yes, by definition, that is the intention behind all digital inclusion, which is a priority for this Government, because we want everyone to have the access, skills, support and confidence to participate in a modern digital society, whatever their circumstances. We also understand that digital exclusion disproportionately impacts certain demographics, including older people.
That is why, as we develop our approach to tackling this issue, we are working closely with key partners in the third sector, industry and local authorities to base interventions on and target them to individual needs. I hope to say more on this in the near future.
Communications providers have a statutory responsibility to take measures to identify, prepare for and reduce anything that compromises the availability, performance or functionality of their networks and services. Some mobile phone masts have battery back-up so that they can continue operating despite a power outage, although the amount of back up currently varies across the access network.
Ofcom have recently undertaken a public Call for Input on this issue, and in September 2024 they announced they will undertake further analysis to consider whether additional measures are needed. Government will continue working closely with Ofcom, mobile operators and the power sector to ensure there is appropriate and proportionate resilience across the network.
The Government Digital Service (GDS) monitors the accessibility of public sector websites and mobile applications under The Public Sector Bodies (Websites and Mobile Applications) (No. 2) Accessibility Regulations 2018. Between January 2022 and September 2024, GDS monitored 1,203 websites and 21 mobile applications.
Accessibility monitoring of public sector websites and mobile applications is ongoing.
The monitoring process for each website consists of both automated and manual accessibility checks, including keyboard testing.
More information on the monitoring methodology can be found at https://www.gov.uk/guidance/accessibility-monitoring-how-we-test .
The Government is committed to implementing all remaining provisions of the Product Security and Telecommunications Act 2022 as soon as possible. These measures will help deliver the benefits of advanced digital connectivity.
Most provisions have already been implemented. Those remaining are complex and technical. The Department will bring forward a consultation on the implementation of sections 61 to 64, including transitional provisions, as soon as possible.
The Government is committed to implementing all remaining provisions of the Product Security and Telecommunications Act 2022 as soon as possible. These measures will help deliver the benefits of advanced digital connectivity.
Most provisions have already been implemented. Those remaining are complex and technical. The Department will bring forward a consultation on the implementation of sections 61 to 64, including transitional provisions, as soon as possible.
The Government is committed to implementing all remaining provisions of the Product Security and Telecommunications Act 2022 as soon as possible. These measures will help deliver the benefits of advanced digital connectivity.
Most provisions have already been implemented. Those remaining are complex and technical. The Department will bring forward a consultation on the implementation of sections 61 to 64, including transitional provisions, as soon as possible.
Artificial Intelligence (AI) is central to the Government’s plan to kickstart an era of economic growth. The AI Opportunities Action Plan sets out how we will lay the foundations for AI growth, driving adoption and building UK capability.
The Intellectual Property Office identified copyright, digital replicas, and computer-generated works as potential high-impact areas. The Government is consulting to gather evidence of the impact of AI to inform future policy development.
We are looking at the broader IP system to ensure it supports the AI sector, while continuing to protect the UK’s strengths in traditional innovation and creativity.
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
Uveitis | NIHR did not commit any specific funding for uveitis research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for uveitis research was £248,809 for 1 award (1 award from MRC). |
Cataract | NIHR allocated £2,584,219 for research concerning cataracts research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for cataract research was £516,566 for 1 award (1 award from Innovate UK). |
Keratoconus | NIHR allocated £49,458 for research concerning keratoconus research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for keratoconus research was £516,566 for 1 award (1 award from Innovate UK). |
Blepharitis | NIHR did not commit any specific funding for blepharitis research in financial year 2023-24. | UKRI did not commit any specific funding for blepharitis research in 2023-24. |
Central Retinal Vein Occlusion | NIHR allocated £70,000 for research concerning central retinal vein occlusion in the financial year 2023-24. | UKRI did not commit any specific funding for central retinal vein occlusion research in 2023-24. |
Retinal Detachment Occlusion Research | NIHR did not commit any specific funding for retinal detachment occlusion research in financial year of 2023-24. | The total commitment across UKRI in 2023-24 for retinal detachment occlusion research was £1,223,830 for 1 award (1 award from MRC). |
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
Uveitis | NIHR did not commit any specific funding for uveitis research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for uveitis research was £248,809 for 1 award (1 award from MRC). |
Cataract | NIHR allocated £2,584,219 for research concerning cataracts research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for cataract research was £516,566 for 1 award (1 award from Innovate UK). |
Keratoconus | NIHR allocated £49,458 for research concerning keratoconus research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for keratoconus research was £516,566 for 1 award (1 award from Innovate UK). |
Blepharitis | NIHR did not commit any specific funding for blepharitis research in financial year 2023-24. | UKRI did not commit any specific funding for blepharitis research in 2023-24. |
Central Retinal Vein Occlusion | NIHR allocated £70,000 for research concerning central retinal vein occlusion in the financial year 2023-24. | UKRI did not commit any specific funding for central retinal vein occlusion research in 2023-24. |
Retinal Detachment Occlusion Research | NIHR did not commit any specific funding for retinal detachment occlusion research in financial year of 2023-24. | The total commitment across UKRI in 2023-24 for retinal detachment occlusion research was £1,223,830 for 1 award (1 award from MRC). |
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
Uveitis | NIHR did not commit any specific funding for uveitis research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for uveitis research was £248,809 for 1 award (1 award from MRC). |
Cataract | NIHR allocated £2,584,219 for research concerning cataracts research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for cataract research was £516,566 for 1 award (1 award from Innovate UK). |
Keratoconus | NIHR allocated £49,458 for research concerning keratoconus research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for keratoconus research was £516,566 for 1 award (1 award from Innovate UK). |
Blepharitis | NIHR did not commit any specific funding for blepharitis research in financial year 2023-24. | UKRI did not commit any specific funding for blepharitis research in 2023-24. |
Central Retinal Vein Occlusion | NIHR allocated £70,000 for research concerning central retinal vein occlusion in the financial year 2023-24. | UKRI did not commit any specific funding for central retinal vein occlusion research in 2023-24. |
Retinal Detachment Occlusion Research | NIHR did not commit any specific funding for retinal detachment occlusion research in financial year of 2023-24. | The total commitment across UKRI in 2023-24 for retinal detachment occlusion research was £1,223,830 for 1 award (1 award from MRC). |
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
Uveitis | NIHR did not commit any specific funding for uveitis research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for uveitis research was £248,809 for 1 award (1 award from MRC). |
Cataract | NIHR allocated £2,584,219 for research concerning cataracts research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for cataract research was £516,566 for 1 award (1 award from Innovate UK). |
Keratoconus | NIHR allocated £49,458 for research concerning keratoconus research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for keratoconus research was £516,566 for 1 award (1 award from Innovate UK). |
Blepharitis | NIHR did not commit any specific funding for blepharitis research in financial year 2023-24. | UKRI did not commit any specific funding for blepharitis research in 2023-24. |
Central Retinal Vein Occlusion | NIHR allocated £70,000 for research concerning central retinal vein occlusion in the financial year 2023-24. | UKRI did not commit any specific funding for central retinal vein occlusion research in 2023-24. |
Retinal Detachment Occlusion Research | NIHR did not commit any specific funding for retinal detachment occlusion research in financial year of 2023-24. | The total commitment across UKRI in 2023-24 for retinal detachment occlusion research was £1,223,830 for 1 award (1 award from MRC). |
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
Uveitis | NIHR did not commit any specific funding for uveitis research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for uveitis research was £248,809 for 1 award (1 award from MRC). |
Cataract | NIHR allocated £2,584,219 for research concerning cataracts research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for cataract research was £516,566 for 1 award (1 award from Innovate UK). |
Keratoconus | NIHR allocated £49,458 for research concerning keratoconus research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for keratoconus research was £516,566 for 1 award (1 award from Innovate UK). |
Blepharitis | NIHR did not commit any specific funding for blepharitis research in financial year 2023-24. | UKRI did not commit any specific funding for blepharitis research in 2023-24. |
Central Retinal Vein Occlusion | NIHR allocated £70,000 for research concerning central retinal vein occlusion in the financial year 2023-24. | UKRI did not commit any specific funding for central retinal vein occlusion research in 2023-24. |
Retinal Detachment Occlusion Research | NIHR did not commit any specific funding for retinal detachment occlusion research in financial year of 2023-24. | The total commitment across UKRI in 2023-24 for retinal detachment occlusion research was £1,223,830 for 1 award (1 award from MRC). |
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
Uveitis | NIHR did not commit any specific funding for uveitis research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for uveitis research was £248,809 for 1 award (1 award from MRC). |
Cataract | NIHR allocated £2,584,219 for research concerning cataracts research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for cataract research was £516,566 for 1 award (1 award from Innovate UK). |
Keratoconus | NIHR allocated £49,458 for research concerning keratoconus research in financial year 2023-24. | The total commitment across UKRI in 2023-24 for keratoconus research was £516,566 for 1 award (1 award from Innovate UK). |
Blepharitis | NIHR did not commit any specific funding for blepharitis research in financial year 2023-24. | UKRI did not commit any specific funding for blepharitis research in 2023-24. |
Central Retinal Vein Occlusion | NIHR allocated £70,000 for research concerning central retinal vein occlusion in the financial year 2023-24. | UKRI did not commit any specific funding for central retinal vein occlusion research in 2023-24. |
Retinal Detachment Occlusion Research | NIHR did not commit any specific funding for retinal detachment occlusion research in financial year of 2023-24. | The total commitment across UKRI in 2023-24 for retinal detachment occlusion research was £1,223,830 for 1 award (1 award from MRC). |
The SME Digital Adoption Taskforce led by Phil Smith and reporting to DBT is looking specifically at SMEs adopting technology. They are working towards their interim report. The National Technology Adviser and Government Chief Scientific Adviser are running an official Government review reporting to the Chancellor, DBT SoS and DSIT SoS that identifies barriers that businesses within the Industrial Strategy’s 8 growth sectors face when adopting established and novel technologies. This is then related to productivity and growth of the economy. It is building on existing analysis, industry insights and other government reviews and workstreams. Recommendations will feed directly into Industrial Strategy work.
The UK’s immigration offer enables talented scientists, researchers and innovators to come to the UK through a number of visa routes such as the Global Talent visa, the High Potential Individual visa and the Skilled Worker visa, and we continually keep our policies under review.
The Department for Science, Innovation and Technology has regular discussions with the Home Office, and with other Government Departments, to ensure that the UK’s world-class science, research, technology and innovation sectors are supported.
UKRI allows researchers coming to the UK who are working at least 50% of their time on a UKRI grant to claim the cost of their visa from the grant. Many other research funders operate a similar policy. Researchers in receipt of Horizon Europe grants are also allowed to claim the cost of their visa from their grant.
The Regulatory Innovation Office (RIO) was formally established on 8th October 2024. Initially it is supporting the growth of four fast-growing areas of technology. These are: Engineering biology, Space, Artificial Intelligence and digital in healthcare; and Drones and other autonomous technology. In developing the next priority areas, the RIO will explore a wide range of technologies.
The Government Office for Technology Transfer (GOTT) helps accelerate government’s innovations towards the market, to impact growth and deliver new products and services for citizens. GOTT provides expertise, funding, and guidance to central government departments and arm’s length bodies across the spectrum of technologies. Since July 2024 there have been no specific discussions between the Secretary of State and GOTT on its approach to supporting market innovation into nanotechnology.
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
open-angle glaucoma | NIHR allocated £140,000 for open-angle Glaucoma research in 2023-24 | The total commitment across UKRI in 2023-24 for glaucoma research was £1,209,175 for 3 awards (1 award from Innovate UK; 2 awards from MRC). |
closed-angle glaucoma | NIHR did not commit any specific funding for closed-angle glaucoma research during the financial year of 2023-24. | |
wet macular degeneration | NIHR did not commit any specific funding for wet macular degeneration research during the financial year of 2023-24. | The total commitment across UKRI in 2023-24 for macular degeneration research was £3,941,644 for 11 awards (1 award from BBSRC; 3 awards from EPSRC; 1 award from Innovate UK; 3 awards from MRC; 2 awards from centrally managed UKRI schemes). |
dry macular degeneration | NIHR did not commit any specific funing for dry macular degeneration research during the financial year of 2023-24. | |
diabetic retinopathy | NIHR allocated £977,340 for diabetic retinopathy research in the financial year 2023-24. | The total commitment across UKRI in 2023-24 for diabetic retinopathy research was £1,068,246 for 2 awards (1 award from Innovate UK; 1 award from EPSRC). |
retinitis pigmentosa | NIHR did not commit any specific funding for retinitis pigmentosa research during financial year 2023-24. | UKRI did not commit any specific funding for retinitis pigmentosa research in 2023-24. |
retinoblastoma | NIHR did not commit any specific funding for retinoblastoma research during the financial year of 2023-24 | UKRI did not commit any specific funding for retinoblastoma research in 2023-24. |
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
open-angle glaucoma | NIHR allocated £140,000 for open-angle Glaucoma research in 2023-24 | The total commitment across UKRI in 2023-24 for glaucoma research was £1,209,175 for 3 awards (1 award from Innovate UK; 2 awards from MRC). |
closed-angle glaucoma | NIHR did not commit any specific funding for closed-angle glaucoma research during the financial year of 2023-24. | |
wet macular degeneration | NIHR did not commit any specific funding for wet macular degeneration research during the financial year of 2023-24. | The total commitment across UKRI in 2023-24 for macular degeneration research was £3,941,644 for 11 awards (1 award from BBSRC; 3 awards from EPSRC; 1 award from Innovate UK; 3 awards from MRC; 2 awards from centrally managed UKRI schemes). |
dry macular degeneration | NIHR did not commit any specific funing for dry macular degeneration research during the financial year of 2023-24. | |
diabetic retinopathy | NIHR allocated £977,340 for diabetic retinopathy research in the financial year 2023-24. | The total commitment across UKRI in 2023-24 for diabetic retinopathy research was £1,068,246 for 2 awards (1 award from Innovate UK; 1 award from EPSRC). |
retinitis pigmentosa | NIHR did not commit any specific funding for retinitis pigmentosa research during financial year 2023-24. | UKRI did not commit any specific funding for retinitis pigmentosa research in 2023-24. |
retinoblastoma | NIHR did not commit any specific funding for retinoblastoma research during the financial year of 2023-24 | UKRI did not commit any specific funding for retinoblastoma research in 2023-24. |
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
open-angle glaucoma | NIHR allocated £140,000 for open-angle Glaucoma research in 2023-24 | The total commitment across UKRI in 2023-24 for glaucoma research was £1,209,175 for 3 awards (1 award from Innovate UK; 2 awards from MRC). |
closed-angle glaucoma | NIHR did not commit any specific funding for closed-angle glaucoma research during the financial year of 2023-24. | |
wet macular degeneration | NIHR did not commit any specific funding for wet macular degeneration research during the financial year of 2023-24. | The total commitment across UKRI in 2023-24 for macular degeneration research was £3,941,644 for 11 awards (1 award from BBSRC; 3 awards from EPSRC; 1 award from Innovate UK; 3 awards from MRC; 2 awards from centrally managed UKRI schemes). |
dry macular degeneration | NIHR did not commit any specific funing for dry macular degeneration research during the financial year of 2023-24. | |
diabetic retinopathy | NIHR allocated £977,340 for diabetic retinopathy research in the financial year 2023-24. | The total commitment across UKRI in 2023-24 for diabetic retinopathy research was £1,068,246 for 2 awards (1 award from Innovate UK; 1 award from EPSRC). |
retinitis pigmentosa | NIHR did not commit any specific funding for retinitis pigmentosa research during financial year 2023-24. | UKRI did not commit any specific funding for retinitis pigmentosa research in 2023-24. |
retinoblastoma | NIHR did not commit any specific funding for retinoblastoma research during the financial year of 2023-24 | UKRI did not commit any specific funding for retinoblastoma research in 2023-24. |
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
open-angle glaucoma | NIHR allocated £140,000 for open-angle Glaucoma research in 2023-24 | The total commitment across UKRI in 2023-24 for glaucoma research was £1,209,175 for 3 awards (1 award from Innovate UK; 2 awards from MRC). |
closed-angle glaucoma | NIHR did not commit any specific funding for closed-angle glaucoma research during the financial year of 2023-24. | |
wet macular degeneration | NIHR did not commit any specific funding for wet macular degeneration research during the financial year of 2023-24. | The total commitment across UKRI in 2023-24 for macular degeneration research was £3,941,644 for 11 awards (1 award from BBSRC; 3 awards from EPSRC; 1 award from Innovate UK; 3 awards from MRC; 2 awards from centrally managed UKRI schemes). |
dry macular degeneration | NIHR did not commit any specific funing for dry macular degeneration research during the financial year of 2023-24. | |
diabetic retinopathy | NIHR allocated £977,340 for diabetic retinopathy research in the financial year 2023-24. | The total commitment across UKRI in 2023-24 for diabetic retinopathy research was £1,068,246 for 2 awards (1 award from Innovate UK; 1 award from EPSRC). |
retinitis pigmentosa | NIHR did not commit any specific funding for retinitis pigmentosa research during financial year 2023-24. | UKRI did not commit any specific funding for retinitis pigmentosa research in 2023-24. |
retinoblastoma | NIHR did not commit any specific funding for retinoblastoma research during the financial year of 2023-24 | UKRI did not commit any specific funding for retinoblastoma research in 2023-24. |
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
open-angle glaucoma | NIHR allocated £140,000 for open-angle Glaucoma research in 2023-24 | The total commitment across UKRI in 2023-24 for glaucoma research was £1,209,175 for 3 awards (1 award from Innovate UK; 2 awards from MRC). |
closed-angle glaucoma | NIHR did not commit any specific funding for closed-angle glaucoma research during the financial year of 2023-24. | |
wet macular degeneration | NIHR did not commit any specific funding for wet macular degeneration research during the financial year of 2023-24. | The total commitment across UKRI in 2023-24 for macular degeneration research was £3,941,644 for 11 awards (1 award from BBSRC; 3 awards from EPSRC; 1 award from Innovate UK; 3 awards from MRC; 2 awards from centrally managed UKRI schemes). |
dry macular degeneration | NIHR did not commit any specific funing for dry macular degeneration research during the financial year of 2023-24. | |
diabetic retinopathy | NIHR allocated £977,340 for diabetic retinopathy research in the financial year 2023-24. | The total commitment across UKRI in 2023-24 for diabetic retinopathy research was £1,068,246 for 2 awards (1 award from Innovate UK; 1 award from EPSRC). |
retinitis pigmentosa | NIHR did not commit any specific funding for retinitis pigmentosa research during financial year 2023-24. | UKRI did not commit any specific funding for retinitis pigmentosa research in 2023-24. |
retinoblastoma | NIHR did not commit any specific funding for retinoblastoma research during the financial year of 2023-24 | UKRI did not commit any specific funding for retinoblastoma research in 2023-24. |
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
open-angle glaucoma | NIHR allocated £140,000 for open-angle Glaucoma research in 2023-24 | The total commitment across UKRI in 2023-24 for glaucoma research was £1,209,175 for 3 awards (1 award from Innovate UK; 2 awards from MRC). |
closed-angle glaucoma | NIHR did not commit any specific funding for closed-angle glaucoma research during the financial year of 2023-24. | |
wet macular degeneration | NIHR did not commit any specific funding for wet macular degeneration research during the financial year of 2023-24. | The total commitment across UKRI in 2023-24 for macular degeneration research was £3,941,644 for 11 awards (1 award from BBSRC; 3 awards from EPSRC; 1 award from Innovate UK; 3 awards from MRC; 2 awards from centrally managed UKRI schemes). |
dry macular degeneration | NIHR did not commit any specific funing for dry macular degeneration research during the financial year of 2023-24. | |
diabetic retinopathy | NIHR allocated £977,340 for diabetic retinopathy research in the financial year 2023-24. | The total commitment across UKRI in 2023-24 for diabetic retinopathy research was £1,068,246 for 2 awards (1 award from Innovate UK; 1 award from EPSRC). |
retinitis pigmentosa | NIHR did not commit any specific funding for retinitis pigmentosa research during financial year 2023-24. | UKRI did not commit any specific funding for retinitis pigmentosa research in 2023-24. |
retinoblastoma | NIHR did not commit any specific funding for retinoblastoma research during the financial year of 2023-24 | UKRI did not commit any specific funding for retinoblastoma research in 2023-24. |
The Department of Health and Social Care funds medical research through the National Institute for Health and Care Research (NIHR). The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology was awarded £20 million funding for a five-year period starting from December 2022.
UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally. UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological, and mechanistic aspects that are applicable to many eye diseases and disorders of vision.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in 2023/24 |
open-angle glaucoma | NIHR allocated £140,000 for open-angle Glaucoma research in 2023-24 | The total commitment across UKRI in 2023-24 for glaucoma research was £1,209,175 for 3 awards (1 award from Innovate UK; 2 awards from MRC). |
closed-angle glaucoma | NIHR did not commit any specific funding for closed-angle glaucoma research during the financial year of 2023-24. | |
wet macular degeneration | NIHR did not commit any specific funding for wet macular degeneration research during the financial year of 2023-24. | The total commitment across UKRI in 2023-24 for macular degeneration research was £3,941,644 for 11 awards (1 award from BBSRC; 3 awards from EPSRC; 1 award from Innovate UK; 3 awards from MRC; 2 awards from centrally managed UKRI schemes). |
dry macular degeneration | NIHR did not commit any specific funing for dry macular degeneration research during the financial year of 2023-24. | |
diabetic retinopathy | NIHR allocated £977,340 for diabetic retinopathy research in the financial year 2023-24. | The total commitment across UKRI in 2023-24 for diabetic retinopathy research was £1,068,246 for 2 awards (1 award from Innovate UK; 1 award from EPSRC). |
retinitis pigmentosa | NIHR did not commit any specific funding for retinitis pigmentosa research during financial year 2023-24. | UKRI did not commit any specific funding for retinitis pigmentosa research in 2023-24. |
retinoblastoma | NIHR did not commit any specific funding for retinoblastoma research during the financial year of 2023-24 | UKRI did not commit any specific funding for retinoblastoma research in 2023-24. |
Our immediate focus is getting the Online Safety Act (OSA) implemented quickly and effectively. The OSA sets out a clear regulatory framework to tackle both mis- and disinformation where it constitutes illegal content or harmful content to children.
In addition, through our work on media literacy, we are taking steps to empower users with the skills they need to engage critically with online content. Since 2022, we have provided almost £3million in funding to projects helping citizens make safer, more informed decisions online.
Officials also regularly meet with major social media platforms to discuss disinformation activity, emerging risks and platforms’ responses.
The government is committed to supporting families who have endured unimaginable losses. The Online Safety Act will help address challenges faced by bereaved parents when engaging with online services following a child’s death. The Act gives Ofcom the power to require information from regulated services about a deceased child’s online activity following a coroner’s request.
In terms of horrific abusive content, under the Act social media platforms must take responsibility for users’ safety by removing illegal abusive content. These duties on platforms to tackle illegal content are expected to come into effect in Spring 2025.
The Government is committed to the rollout of fast, reliable broadband to all parts of the UK. So far we have over 30 Project Gigabit contracts in place, filling in gaps that are not being met commercially, predominantly in rural areas. This includes a contract across South Oxfordshire which will provide approximately 3,500 premises in the Henley and Thame constituency with access to gigabit-capable broadband.
The Government is committed to supporting the uptake, development and evaluation of alternative methods to the use of animals in science and new approach methodologies. It is not yet possible to replace all animal use due to the complexity of biological systems and regulatory requirements for their use.
We recognise that any work to support the transition to new approach methodologies must be science-led and in lock step with partners, and so we are meeting with key stakeholders to pursue this work. We will make any announcements on our plans in due course.
Research and innovation is key to delivering the government’s missions, and universities are essential for this.
We are increasing Core Research funding to over £6.1bn to deliver on the government’s research priorities and offer real terms protection to the UK's world leading universities.
This Government has committed to record funding of R&D in the recent budget. Total HMG investment in R&D is rising to a record allocation of £20.4bn in 2025/26
I set out in my previous answer to the Honourable Member for Stafford, that we are investing £29.8 million in research and innovation projects in Staffordshire.
For example, through the Strength in Places Fund, we are investing £18 million in the Midlands Advanced Ceramics for Industry 4.0 project. This is a consortium of researchers, manufacturers and end-users led by the Lucideon Group, which has sites in Stoke-on-Trent and Stone. It will develop streamlined processes for proving and bringing new advanced ceramics technologies to market faster, with less energy usage and lower carbon emissions.
According to Ofcom’s December 2024 Connected Nations report, just 0.1% of properties are unable to get decent broadband coverage (defined as at least 10 Mbps download speed and 1 Mbps upload speed), with 89% of rural UK residential properties having superfast broadband coverage (>=30 Mbps). Clearly this still leaves a significant number of rural properties with inadequate broadband coverage.
Through Project Gigabit, more than £2 billion of contracts have been signed to connect over a million more premises with gigabit-capable broadband (>1000 Mbps). These premises predominantly fall in rural areas.
For those premises still unable to get a decent broadband connection, the Broadband USO provides consumers the right to request a decent broadband connection.
This Government’s record £20.4 billion investment in R&D for 2025/26 will help people across the UK enjoy the benefits from an innovation-led economy.
My Hon Friend will be pleased to hear, as part of this, we are extending the Innovation Accelerators, including in the Glasgow City Region to grow its globally competitive innovation centre.
An example of one of the many innovative firms we are supporting in Glasgow is Spire Global who were recently awarded over £3.5 million for a unique weather forecasting data project.
The Government is investing £106 million in five new quantum hubs across the UK as part of the National Quantum Technologies Programme. One hub, the UK Hub for Quantum Enabled Position, Navigation and Timing (QEPNT), will be based in Glasgow, leveraging the city’s strengths in photonics and quantum.
These hubs aim to turn cutting-edge science into practical solutions, transforming sectors like healthcare and security, while fostering innovation and driving economic growth, including in Glasgow.
The Government doesn’t ringfence funding for specific diseases but is committed to funding cancer research, including lobular breast cancer. The Department of Health and Social Care spent £121.8 million in 2022/23 on cancer research through the National Institute for Health and Care Research.
The Department for Science, Innovation and Technology funds cancer research via UK Innovation and Research (UKRI). UKRI invests approximately £200 million annually into cancer research, of which £10m per year is for breast cancer research.
Office for Life Sciences’ Cancer Healthcare Goals programme funds innovations at the earlier stages of the research and development pipeline. Such innovations will have the potential to diagnose multiple tumour types, including breast cancer.
We have allocated £1.3 million of funding for a National Institute of Health and Care Research (NIHR) project that will assess the effectiveness of a new form of MRI scan to detect breast cancers that have been missed by mammograms.
Further NIHR research infrastructure funding supports Biomedical Research Centres and the NIHR Research Delivery Network, which has enabled delivery of 10 lobular breast-cancer studies.
It is shocking that the last government published no digital inclusion strategy for 10 years. This Government is determined to remedy that and I hope to be able to say more soon.
The latest data from the independent website Thinkbroadband.com shows that over 85% of UK premises can now access a gigabit-capable connection. We are committed to delivering nationwide gigabit coverage by 2030.
Earlier this week we announced the signing of four additional Project Gigabit contracts with Openreach to extend gigabit connectivity to over 130,000 premises, including in the Hon. Gentleman’s constituency.
As a result, there is now more than £2 billion available in our live contracts to connect over a million premises with gigabit-capable broadband. These are premises that fall predominantly in rural areas.